Marina Shcherba

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

Andrea Cercek, Melissa Lumish, Jenna Sinopoli et al. · New England Journal of Medicine · 2022 · 1.4K citations · Full text

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila et al. · The Lancet Oncology · 2020 · 347 citations · Full text

First-line Pembrolizumab, Esophageal Cancer, Gastrointestinal Oncology +7

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

Haiying Cheng, Marina Shcherba, Gopichand Pendurti et al. · Lung Cancer Management · 2014 · 139 citations · Full text

Nonoperative Management of Mismatch Repair–Deficient Tumors

Andrea Cercek, Michael B. Foote, Benoı̂t Rousseau et al. · New England Journal of Medicine · 2025 · 93 citations · Full text

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

Yelena Y. Janjigian, Joanne F. Chou, Marc Simmons et al. · Journal of Clinical Oncology · 2019 · 48 citations

Esophageal Cancer, Immunology, Immunoediting +23